Evolvere BioSciences

About Evolvere BioSciences

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

<problem> The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing antibiotics ineffective. Traditional antibiotic development struggles to keep pace with the rapid evolution of pathogens, leading to a critical need for new strategies. </problem> <solution> Evolvere BioSciences employs artificial intelligence and co-evolutionary modeling to design novel antibiotics that can overcome bacterial resistance mechanisms. Their approach simulates the evolutionary arms race between bacteria and antibiotics, allowing them to predict and preempt resistance development. By understanding how bacteria evolve in response to drugs, Evolvere BioSciences can create antibiotics that remain effective over longer periods. This proactive strategy aims to provide a sustainable solution to the growing problem of antibiotic resistance. </solution> <features> - AI-driven co-evolutionary models to predict and preempt bacterial resistance - In silico drug design to identify novel antibiotic candidates - High-throughput screening to validate antibiotic efficacy against resistant strains - Optimization of drug candidates for improved potency and pharmacokinetic properties </features> <target_audience> The primary target audience includes pharmaceutical companies, research institutions, and government agencies involved in antibiotic development and combating antimicrobial resistance. </target_audience>

What does Evolvere BioSciences do?

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

Where is Evolvere BioSciences located?

Evolvere BioSciences is based in Oxford, United Kingdom.

When was Evolvere BioSciences founded?

Evolvere BioSciences was founded in 2021.

How much funding has Evolvere BioSciences raised?

Evolvere BioSciences has raised 500000.

Location
Oxford, United Kingdom
Founded
2021
Funding
500000
Employees
6 employees
Major Investors
Y Combinator

Find Investable Startups and Competitors

Search thousands of startups using natural language

Evolvere BioSciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

evolverebiosciences.com700+
cb
Crunchbase
Founded 2021Oxford, United Kingdom

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator

Team (5+)

No team information available.

Company Description

Problem

The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing antibiotics ineffective. Traditional antibiotic development struggles to keep pace with the rapid evolution of pathogens, leading to a critical need for new strategies.

Solution

Evolvere BioSciences employs artificial intelligence and co-evolutionary modeling to design novel antibiotics that can overcome bacterial resistance mechanisms. Their approach simulates the evolutionary arms race between bacteria and antibiotics, allowing them to predict and preempt resistance development. By understanding how bacteria evolve in response to drugs, Evolvere BioSciences can create antibiotics that remain effective over longer periods. This proactive strategy aims to provide a sustainable solution to the growing problem of antibiotic resistance.

Features

AI-driven co-evolutionary models to predict and preempt bacterial resistance

In silico drug design to identify novel antibiotic candidates

High-throughput screening to validate antibiotic efficacy against resistant strains

Optimization of drug candidates for improved potency and pharmacokinetic properties

Target Audience

The primary target audience includes pharmaceutical companies, research institutions, and government agencies involved in antibiotic development and combating antimicrobial resistance.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.